Jan 27, 2026
January 9, 2025
At the 11th Medical Scientists Annual Conference, the 2025 China Top Ten Original Advances in Ophthalmology were officially announced, marking one of the most influential annual milestones in China’s eye-health and medical-technology ecosystem.
The initiative aims to identify, recognize, and promote truly original innovations in ophthalmic science, clinical practice, and medical technology, setting benchmarks for future research directions, industrial development, and global competitiveness.
More importantly, the program highlights breakthroughs that move beyond incremental improvement, emphasizing “0 to 1” foundational innovation with long-term clinical and industrial impact.
The release ceremony was presented by Wang Ningli, Academician of the Chinese Academy of Engineering and President of Beijing Tongren Hospital, affiliated with Capital Medical University.
Professor Wang also serves as Chief Scientific Advisor at Akeso Eyecare, bringing deep academic authority and strategic vision to both national ophthalmic innovation and Akeso’s long-term scientific roadmap.
This year marked the sixth consecutive release of the Top Ten Original Advances by the conference. The selection process is led by the National Engineering Research Center for Ophthalmic Diagnosis and Treatment, under rigorous evaluation standards to ensure true originality, academic rigor, and translational value.
During the announcement, Professor Wang summarized three core characteristics that distinguish this year’s selected innovations.
The 2025 selections demonstrate a clear commitment to original scientific and technological breakthroughs, pushing beyond existing technical boundaries rather than building on derivative or incremental improvements.
Professor Wang emphasized that China’s ophthalmology community has made bold progress in “0 to 1” innovation, with achievements spanning:
Together, these advances form a multi-layered and diversified innovation ecosystem, supporting leapfrog development across the field.
China has largely achieved localization of low-end ophthalmic equipment. More notably, mid- to high-end ophthalmic devices are now entering direct competition with international brands, reflecting substantial gains in domestic R&D capability and industrial maturity.
Reflecting on the broader evolution of ophthalmology in China, Professor Wang described a clear progression:
From “catching up,” to “running alongside,” and in selected areas, to “leading.”
While acknowledging this progress, he stressed that key bottleneck technologies remain critical challenges. Sustained investment and cross-disciplinary collaboration will be essential to achieving long-term independence and leadership.
Looking ahead, Professor Wang projected that within three to five years, China is likely to realize independent breakthroughs across the full ophthalmic value chain, encompassing:
Akeso was included among the 2025 China Top Ten Original Advances in Ophthalmology, recognizing its work in micro–nano lithography–based personalized myopia control lenses, a representative example of original, foundational innovation in vision science and optical engineering.
Against this backdrop, Professor Wang Ningli’s insights closely align with Akeso’s core scientific philosophy, a long-term commitment to original innovation, high-end technology localization, and sustained global competitiveness in ophthalmic science and vision technology. His emphasis on “0 to 1” breakthroughs, precision-driven development, and full-chain technological independence directly reflects the principles underpinning Akeso’s research and product strategy.
His perspectives further reinforce the importance of building a self-sustaining innovation ecosystem, one capable of delivering clinically meaningful, scalable, and internationally competitive solutions, rather than short-term or superficial advancements. For Akeso, this alignment underscores its continued focus on foundational technologies, precision manufacturing, and evidence-based translation from research to real-world clinical impact.
Source:Physician’s Journal | Author: Yang Ruijing https://mp.weixin.qq.com/s/pwk_iDxnu7DwW_BkbJEirw
Akeso Eyecare is a doctor-founded eye-technology company and CDMO focused on improving vision care. We design and build advanced solutions like AR displays for myopia prevention, eye tracking, extended reality devices, and digital vision health tools used in eye care and smart technology.
Our mission is to improve global vision health through smart innovation. By combining optical design, materials science, and AI, our R&D team supports partners from early research to custom design, manufacturing, and large-scale production, always guided by medical expertise, collaboration, sustainability, and patient-first thinking.
Akeso – engineering the future of vision.
Engineering the
Future of Vision.